Pharmaceutical major Dr. Reddy’s Laboratories announced its fourth-quarter results on Tuesday.

What Happened: The drugmaker said its profit grew 36% to ₹1,307 crore for the quarter ended March 31, up from the ₹959.2 crore it earned in the same quarter last year. This was slightly higher than analyst estimates of ₹1,291 crore.

The company’s revenue came in at ₹7,083 crore, up 12% from ₹6,296.8 crore a year ago. The figure was slightly lower than analyst estimates of ₹7,136 crore.

See Also: CG Power Share Price Climbs As Q4 Margins Impresses Analysts

The company’s also board also recommended a dividend of ₹40 per equity share for the year.

The firm’s EBITDA for the quarter grew 14.8% to ₹1,872 crore, higher than the ₹1631.1 crore it made last year.

Revenue from the North America segment grew 29% to ₹3,260 crore but also registered a quarter-on-quarter decline of 3%, owing to a decrease in base business volumes and price erosion in select brands, the company said.

Price Action: Dr. Reddy’s Labs ended the session on Tuesday down 0.32% at ₹6,273.40.

Read Next: Hindalco Shares Down 3% Today But Several Brokerages Raise Targets